Dr. Lal PathLabs Acquires 70% Stake in SN Genelab for Up to INR 199.5 Crores
Dr. Lal PathLabs Ltd 路 Outcome 路 24 Sept 2026, 10:54 pm
Dr. Lal PathLabs Acquires 70% Stake in SN Genelab for Up to INR 199.5 Crores Dr. Lal PathLabs approved the acquisition of a 70% stake in Gujarat-based genomics diagnostic firm SN Genelab on 24th Sep'26. The all-cash transaction is valued at up to INR 168 Crores, alongside performance-linked earnouts capped at INR 31.5 Crores, and is slated for completion by 30th Nov'26. The acquisition aims to enhance the company鈥檚 genomics capabilities and broaden advanced diagnostic offerings. SN Genelab reported turnovers of INR 57.96 Crores in FY26, INR 53.36 Crores in FY25, and INR 43.27 Crores in FY24.
Original exchange filing (PDF)
More announcements from Dr. Lal PathLabs Ltd
- Attached 路 11 Nov 2026
- Attached 路 10 Nov 2026
- Attached 路 05 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
- Attached 路 04 Nov 2026
